An Open-Label, Randomized, Dose-ranging Phase IIa Trial to Determine the Effects of RTA 402 (Bardoxolone Methyl) on Renal Function in Patients With Diabetic Nephropathy.

Trial Profile

An Open-Label, Randomized, Dose-ranging Phase IIa Trial to Determine the Effects of RTA 402 (Bardoxolone Methyl) on Renal Function in Patients With Diabetic Nephropathy.

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Nov 2016

At a glance

  • Drugs Bardoxolone methyl (Primary)
  • Indications Diabetic nephropathies
  • Focus Pharmacodynamics
  • Acronyms Stratum 1
  • Most Recent Events

    • 14 Nov 2016 Results published in the Reata Pharmaceuticals Media Release
    • 24 Jun 2011 Actual end date (May 2009) added as reported by ClinicalTrials.gov.
    • 09 Jun 2009 Results were reported at the 69th Annual Scientific Sessions of the American Diabetes Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top